Login to Your Account



Earnings scorecard


Monday, April 28, 2014
Immunogen Inc., of Waltham, Mass., said partner Roche AG, of Basel, Switzerland, reported global sales of breast cancer drug Kadcyla (ado-trastuzumab emtansine) of CHF102 million (US$115 million) for the first quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription